Clovis Oncology, Inc. (CLVSQ)

OTCMKTS: CLVSQ · Delayed Price · USD
0.153
-0.003 (-2.18%)
Jan 13, 2023, 4:00 PM EST - Market closed
Market Cap 11.77M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) -2.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,590,512
Open 0.144
Previous Close 0.156
Day's Range 0.141 - 0.159
52-Week Range 0.042 - 0.189
Beta 0.22
Analysts n/a
Price Target n/a
Earnings Date Feb 21, 2023

About CLVSQ

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal canc... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 16, 2011
Employees 413
Stock Exchange OTCMKTS
Ticker Symbol CLVSQ
Full Company Profile

Financial Performance

In 2021, CLVSQ's revenue was $148.76 million, a decrease of -9.58% compared to the previous year's $164.52 million. Losses were -$264.52 million, -28.35% less than in 2020.

Financial Statements

News

Bet on 5 Top Stocks With Rising P/E

Forget undervalued stocks, play top-ranked stocks like Clovis Oncology (CLVS), NiSource (NI), DocuSign (DOCU), Root (ROOT) and Endava (DAVA).

Other symbols: DAVADOCUNIROOT
1 month ago - Zacks Investment Research

Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis

Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.

Other symbols: NVS
1 month ago - WSJ

Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid

Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.

1 month ago - Zacks Investment Research

CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy

Clovis Oncology (NASDAQ: CLVS) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection. The first thing that investors need to know about is Clov...

1 month ago - InvestorPlace

Clovis Oncology stock slides 10% premarket after company files for bankruptcy

Clovis Oncology Inc. stock CLVS, -9.94% fell 10% in premarket trade Monday, after the biotech filed for Chapter 11 bankruptcy and said it would sell assets. The company has a commitment for up to $75 ...

1 month ago - Market Watch

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) (“Clovis” or the Company”), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-can...

1 month ago - Business Wire

Dear CLVS Stock Fans, Get Ready for a Bankruptcy Filing

Investors in Clovis Oncology (NASDAQ: CLVS) stock will want to prepare for a bankruptcy filing following a warning from the pharmaceutical company. According to a filing with the U.S. Securities and ...

1 month ago - InvestorPlace

Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why

Clovis Oncology (CLVS) tanks in the past six months following the possibility of a bankruptcy filing in the near term.

2 months ago - Zacks Investment Research

Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)

Clovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea...

2 months ago - Zacks Investment Research

7 Stocks to Sell Right Now

Once again, I drew the short (no pun intended) end of the stick and must discuss stocks to sell right now. Understandably a sensitive topic and one that arouses myriad emotions, I'm just going to stic...

Other symbols: AUMNINTZLEDSPBIOSTCN
2 months ago - InvestorPlace

Clovis Oncology (CLVS) Stock Pops After Bankruptcy Warning

There's nothing like a good old-fashioned bankruptcy warning to make a stock pop on a given day. Today, the latest speculative frenzy appears to be underway with Clovis Oncology (NASDAQ: CLVS).

2 months ago - InvestorPlace

Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

2 months ago - Zacks Investment Research

Why Is Clovis Oncology (CLVS) Stock Down 72% Today?

Clovis Oncology (NASDAQ: CLVS) stock is crashing on Wednesday as investors react to news of the company running out of cash! According to a recent filing from Clovis Oncology, there's a strong chance...

2 months ago - InvestorPlace

Clovis Oncology stock slides 75% after biotech warns it will run out of cash by January of 2023

Clovis Oncology Inc. shares CLVS, -73.37% plunged 75% Wednesday, after the Colorado-based biotech said it will not have sufficient liquidity to maintain operations beyond January of 2023. The company ...

2 months ago - Market Watch

Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of 7.14% and 11.87%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Cancer drugmaker Clovis flags possible bankruptcy

U.S. drugmaker Clovis Oncology said on Wednesday it was likely to file for bankruptcy "in the very near term", as the company struggles to sell its cancer drug Rubraca.

2 months ago - Reuters

Will Clovis Oncology (CLVS) Report Negative Q3 Earnings? What You Should Know

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Why Is Clovis Oncology (CLVS) Stock Up Today?

In a still-fresh press release, Clovis Oncology (NASDAQ: CLVS) just announced that its Phase 3 trial for Rubraca, a prostate cancer treatment, achieved its primary endpoint. Moreover, Clovis plans to...

4 months ago - InvestorPlace

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology, Inc. (NASDAQ: CLVS) today announced positive top-line data from the Phase 3, open-label, multicenter, randomized TRITON3 trial demonstrating...

4 months ago - Business Wire

What Is Going on With Clovis Oncology (CLVS) Stock Today?

Source: rafapress / Shutterstock.com Clovis Oncology (NASDAQ: CLVS) stock is getting a boost on Wednesday as investors react to news of it reaching a two-year clinical supply agreement. That agreemen...

4 months ago - InvestorPlace

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

BOULDER, Colo. & PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CLVS--Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

4 months ago - Business Wire

Clovis (CLVS) Seeks Nod for Rubraca in First Line Ovarian Cancer

Clovis (CLVS) files regulatory applications in the United States and Europe seeking label expansion for its sole marketed drug as a first-line maintenance treatment in advanced ovarian cancer.

4 months ago - Zacks Investment Research

Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer

BOULDER, Colo.--(BUSINESS WIRE)---- $CLVS--Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with AOC

4 months ago - Business Wire